Development of experimental GBS vaccine for mucosal immunization

Gupalova, Tatiana; Leontieva, Galina; Kramskaya, Tatiana; Grabovskaya, K. B.; Bormotova, Elena; Korjevski, D.; Suvorov, Alexander

doi:10.1371/journal.pone.0196564

Cited by 18 publications

(23 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, Gupalova et al [60] developed a live vaccine based on the beta antigen C (Bac) protein of serotypes Ia, Ib, II, V, and IX of GBS. They used the probiotic strain Enterococcus faecium L3 for mucosal immunization.…”

Section: Discussionmentioning

confidence: 99%

Mucosal Vaccination with Lactococcus lactis-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B Streptococcus in a Murine Model

et al. 2020

View full text Add to dashboard Cite

Group B Streptococcus (GBS) is the primary etiological agent of sepsis and meningitis in newborns and is associated with premature birth and stillbirth. The development of a licensed vaccine is one of the pending challenges for the World Health Organization. Previously, we showed that oral immunization with surface immune protein (SIP) decreases vaginal colonization of GBS and generates functional opsonizing antibodies, which was determined by opsonophagocytic assays (OPA) in vitro. We also showed that the protein has an adjuvant vaccine profile. Therefore, an oral vaccine based on SIP may be an attractive alternative to employ in the development of new vaccines against GBS. Lactococcus lactis is a highlighted oral vaccine probiotic inducer of the mucosal immune response. This bacterium could serve as an antigen-delivering vehicle for the development of an edible vaccine and has been used in clinical trials. In this study, we showed that an oral vaccine with a recombinant L. lactis strain secreting SIP from GBS (rL. lactis-SIP) can induce protective humoral and cellular immunity in an experimental model of GBS vaginal colonization in C57BL/6 mice. Mice immunized with rL. lactis-SIP were protected against clinical symptoms and bacterial colonization after GBS vaginal colonization. Our rL. lactis-SIP vaccine also induces an increase of immunoglobulin G (IgG) and immunoglobulin A (IgA) specifically against SIP. The adoptive transfer of serum from vaccinated mice to naïve mice generated protection against GBS vaginal colonization. Moreover, the rL. lactis-SIP strain induces the activation of SIP-specific T cells, which could decrease GBS vaginal colonization and generate protective antibodies when transferred to other mice. Our experimental observations strongly support the notion that rL. lactis-SIP induces protective humoral and cellular immunity and could be considered as a novel alternative in the development of vaccines for GBS.

show abstract

Section: Discussionmentioning

confidence: 99%

Mucosal Vaccination with Lactococcus lactis-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B Streptococcus in a Murine Model

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Previously, we developed a technology for the introduction of DNA constructs into genes that encode fimbrial proteins located on the surface of probiotic enterococci. For this purpose we had created and inserted into the enterococcus a chimeric fimbrial protein d2 containing the immunogenic fragment of the Bac streptococcal protein, and tested it as a possible protective group B streptococcal vaccine [6]. In the present paper, this method was applied for making a probiotic live vaccine against S .…”

Section: Resultsmentioning

confidence: 99%

“…Chromosomal DNA was isolated in order to use the probiotic strain Enterococcus faecium L3 chromosome as a template in a polymerase chain reaction (PCR). A plasmid pspf DNA was used as a template in order to amplify a portion of pspf gene as described in detail previously [4, 6].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Development of experimental pneumococcal vaccine for mucosal immunization

et al. 2019

Self Cite

View full text Add to dashboard Cite

Streptococcus pneumonia is an important human pathogen that causes various severe diseases such as pneumonia, otitis and meningitis. Vaccination against S . pneumoniae is implemented in many developed countries. The presently used vaccines are safe, well tolerated but relatively expensive and require modification due to the immunological changes of the epidemic strains. This paper describes the development of a new pneumococcal vaccine candidate for immunization on mucosal surfaces. For this purpose the antigens of chimeric protein PSPF, previously suggested for an injectable S . pneumoniae vaccine, were expressed on the surface of the live probiotic strain Enterococcus faecium L3. Experiments on laboratory mice vaccinated with live bacteria demonstrated the appearance of the specific IgA and IgG which provide protection against the lethal S . pneumoniae infection.

show abstract

“…That is why we decided to study immunogenicity and protection against pneumococcal infection of ScaAB, which is the major surface lipoprotein of GBS closely related to PsaA protein of S . pneumoniae [16]. PsaA protein is considered to be the most promising vaccine candidate against S .…”

Section: Discussionmentioning

confidence: 99%

Mucosal vaccine based on attenuated influenza virus and the group B Streptococcus recombinant peptides protected mice from influenza and S. pneumoniae infections

et al. 2019

Self Cite

View full text Add to dashboard Cite

Although many influenza-related deaths are attributable to secondary bacterial infection with S . pneumoniae , vaccines that simultaneously protect against influenza and pneumococcal infection are currently not developed. The aim of our study was to evaluate the possibility to prevent post-influenza pneumococcal infection using an associated vaccine based on live influenza vaccine (LAIV) combined with recombinant polypeptides derived from superficial factors of Group B streptococcus (GBS) determining pathogenicity. We demonstrated in a model of post-influenza pneumococcal pneumonia that intranasal pneumococcal super-infection seriously complicated the course of A/Shanghai/2/2013(H7N9) CDC-RG virus infection in mice. Associated immunization using LAIV and GBS vaccine (GBSV) prevented post-influenza pneumococcal pneumonia better than mono-LAIV or GBSV immunization. At the same time, parenteral pneumococcal post-influenza infection of immune mice was more severe in the groups immunized using recombinant GBS peptides which can be explained by antibody-dependent enhancement of infection. In this case, the introduction of blockers of histamine receptors type 1 and 2 reduced the burden of secondary pneumococcal infection.

show abstract

Development of experimental GBS vaccine for mucosal immunization

Cited by 18 publications

References 27 publications

Mucosal Vaccination with Lactococcus lactis-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B Streptococcus in a Murine Model

Mucosal Vaccination with Lactococcus lactis-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B Streptococcus in a Murine Model

Development of experimental pneumococcal vaccine for mucosal immunization

Mucosal vaccine based on attenuated influenza virus and the group B Streptococcus recombinant peptides protected mice from influenza and S. pneumoniae infections

Contact Info

Product

Resources

About